HC Wainwright & Co. reiterates Buy rating on Connect Biopharma Hldgs, $7 price target
HC Wainwright & Co. maintained a Buy rating on Connect Biopharma Hldgs with a $7 price target, suggesting a 730.9% upside from the last close. The firm cited strong clinical data for rademikibart, showing an 81% reduction in treatment failure, and its unique approach to managing COPD exacerbations.
How this was made
The 30-second read
Why it matters
The upgrade could trigger buying pressure and raise the stock’s valuation significantly.
Market read
New clinical data and analyst upgrade provide fresh catalyst for a micro‑cap biotech, offering a potential trade opportunity.
What to watch
Potential regulatory hurdles and competition from established COPD therapies.
Background
Analyst note from HC Wainwright highlighting new clinical trial results and a revised price target.
Market effects
Positive signal for the COPD/respiratory biotech sector may lift peer valuations.
Limited to US biotech and small‑cap investors.
Modest; primarily affects niche biotech investors.
Counterpoint
The trial size is small and results need confirmation; the target may be overly optimistic.
Key entities
- companyConnect Biopharma Holdings Inc.
Biotech firm developing rademikibart for acute COPD exacerbations.
- analystHC Wainwright & Co.
Equity research firm that issued the Buy rating and $7 target.